SEARCH WITHIN CONTENT
Citation Information : Polish Journal of Microbiology. Volume 66, Issue 1, Pages 125-129, DOI: https://doi.org/10.5604/17331331.1235001
License : (CC BY-NC-ND 4.0)
Received Date : 13-January-2017 / Accepted: 02-February-2017 / Published Online: 30-March-2017
We compared association of Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa and Enterococcus faecalis with nine vascular implants after co-culture. Vascular implants were composed of various materials such as warp knitted polyester (with or without gelatin and silver ions), expanded polytetrafluoroethylene and biological materials – surface treated porcine pericardial patch and Omniflow II. The lowest overall number of associated bacteria was detected for polytetrafluoroethylene implants and porcine pericardial patch. The highest overall number of associated bacteria was detected for Omniflow II implant. The major source of variation, i.e. primary factor influencing colonization, is the implant type (56.22%), bacterial species is responsible for only 1.81%, and interaction of those two factors – 13.09% of variation.
Antonios V.S., A.A. Noel, J.M. Steckelberg, R.M. Wilson,J.N. Mandrekar, W.S. Harmsen and L.M. Baddour. 2006. Pro-sthetic vascular graft infection: a risk factor analysis using a case-control study. J. Infect. 53: 49–55.
Avşar M.K., H.H. Poyrazoglu, S. Demir and H. Atli. 2013. Early results of peripheral arterial performed using shelhigh no-react treated internal mammary arteries. Ital. J. Vasc. Endovasc. Surg. 20: 221–223.
Bandyk D.F., T.M. Bergamini, E.V. Kinney, G.R. Seabrook and J.B. Towne. 1991. In situ replacement of vascular protheses infected by bacterial biofilms. J. Vasc. Surg. 13: 575–583.
Bozoglan O., B. Mese, E. Eroglu, S. Elveren, M. Gul, A. Celik,H.I. Yildirimdemir, H. Ciralik and A. Yasim. 2016. Which prosthesis is more resistant to vascular graft infection: polytetrafluoroethylene or Omniflow II biosynthetic grafts? Surg. Today. 46: 363–370.
Bronk M. and A. Samet. 2008. Hospital enterococcal bacteremias. Post. Mikrobiol. 47: 339–344.
Chiesa R., D. Astore, S. Frigerio, L. Garriboli, G. Piccolo, R. Castellano, M. Scalamogna, A. Odero, S. Pirrelli, G. Biasi and others. 2002. Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment. Acta Chir. Belg. 102: 238–247.
Dünschede F., J. Stabrauskaite, G. Weisser, C. Espinola-Klein, B. Dorweiler and C.F. Vahl. 2015. Crural bypass for critical lower limb ischemia with Omniflow II prosthesis. Thorac. Cardiovasc. Surg. 64: 311–315.
Giacometti A., O. Cirioni, R. Ghiselli, L. Goffi, F. Mocchegiani, A. Riva, G. Scalise and V. Saba. 2000. Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. J. Antimicrob. Chemother. 46:751–756.
Grubbs F.E. 1950. Sample criteria for testing outlying observations. Ann. Math. Stat. 21(1): 27–58.
Herrera F.A., S. Kohanzadeh, Y. Nasseri, N. Kansal, E.L. Owens and R. Bodor. 2009. Management of vascular graft infections with soft tissue flap coverage: improving limb salvage rates – a veterans affairs experience. Am. Surg. 75: 877–881.
Jensen L.P., M. Lepäntalo, J.E. Fossdal, O.C. Røder, B.S. Jensen, M.S. Madsen, O. Grenager, H. Fasting, H.O. Myhre, N. Baekgaard and others. 2007. Dacron or PTFE for above-knee femoropopliteal bypass. a multicenter randomised study. Eur. J. Vasc. Endovasc. Surg. 34: 44–49.
Krasznai A.G., M. Snoeijs, M.P. Siroen, T. Sigterman, A. Korsten, F.L. Moll and L.H. Bouwman. 2016. Treatment of aortic graft infection by in situ reconstruction with Omniflow II biosynthetic prosthesis. Vascular. 24: 561–566.
Musci M., A. Amiri, H. Siniawski, J. Stein, Y. Weng and R. Hetzer.2013. Further experience with the “no-react” bioprosthesis in patients with active infective endocarditis: 11-year single center results in 402 patients. Thorac Cardiovasc. Surg. 61: 398–408.
Palumbo R., P. Niscola, S. Calabria, S. Fierimonte, M. Bevilacqua, L. Scaramucci, B. Tolu, P. de Fabritiis and F. Bondanini. 2009. Long-term favorable results by arteriovenous graft with Omniflow II prosthesis for hemodialysis. Nephron. Clin. Pract. 1132: 76–80.
Post S., T. Kraus, U. Müller-Reinartz, C. Weiss, H. Kortmann,A. Quentmeier, M. Winkler, K.J. Husfeldt and J.R. Allenberg. 2001. Dacron vs polytetrafluoroethylene grafts for femoropopliteal bypass: a prospective randomised multicentre trial. Eur. J. Vasc. Endovasc. Surg. 22: 226–231.
Schmitt D.D., D.F. Bandyk, A.J.P equet and J.B. Towne. 1986. Bacterial adherence to vascular prostheses. A determinant of graft infectivity. J. Vasc. Surg. 3: 732–740.
Töpel I., T. Betz, C. Uhl, M. Wiesner, S. Bröckner and M. Steinbauer. 2012. Use of biosynthetic prosthesis (Omniflow II) to replace infected infrainguinal prosthetic grafts – first results. Vasa. 413: 215–220.
Werkmeister J.A., J.F. White, G.A. Edwards and J.A. Ramshaw. 1995. Early performance appraisal of the Omniflow II Vascular Prosthesis as an indicator of long-term function. J. Long Term. Eff. Med. Implants. 5: 1–10.
Yasim A., M. Gul, H. Ciralik and Y. Ergun. 2006. Gelatin-sealed dacron graft is not more susceptible to MRSA infection than PTFE graft. Eur. J. Vasc. Endovasc. Surg. 32: 425–430.